United States

EMD Serono to open $115M life science campus in Massachusetts

Tuesday, July 19, 2016

EMD Serono, known as Merck outside of the U.S. and Canada, a science and technology company, has announced plans to build a new campus in Burlington, Massachusetts, that will serve as a major hub for the North American life science business of Merck. The 280,000-square-foot facility will include a customer collaboration laboratory and training center as well as office space.

[Read More]

Study: Mentorship programs build long-term research careers

Tuesday, July 19, 2016

A public-private mentored research program based at the NIH called the NIH Clinical Research Training Program (CRTP) has helped foster the careers of research-oriented medical and dental students, and similar programs may help bolster the dwindling pipeline of biomedical researchers and clinician-scientists, according to a study now available electronically in Academic Medicine.

[Read More]

NIH expands investment in HIV cure research

Tuesday, July 19, 2016

The NIH has awarded approximately $30 million in annual funding over the next five years to six research collaborations working to advance basic medical science toward an HIV cure. The awards comprise the second iteration of the Martin Delaney Collaboratory: Towards an HIV-1 Cure program and are a part of President Barack Obama’s pledge to invest in HIV cure research. The research program is supported by the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute on Drug Abuse, the National Institute of Mental Health and the National Institute of Neurological Disorders and Stroke, all part of the NIH.

[Read More]

Virginia Cancer Specialists receives Clinical Trials Research Award

Thursday, July 14, 2016

Virginia Cancer Specialists (VCS), Northern Virginia’s premier cancer care center with more than 40 years of service to patients battling cancer and blood diseases, has announced it is one of only three community oncology practices in the country recognized this year by the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) for its commitment to providing high-quality clinical trials to patients.

[Read More]

AbbVie receives Rare Pediatric Disease Designation for ABT-414

Tuesday, July 12, 2016

AbbVie, a global biopharmaceutical company, announced that the FDA granted Rare Pediatric Disease Designation for ABT-414, an investigational antibody drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR), for the treatment of pediatric patients with EGFR-amplified Diffuse Intrinsic Pontine Glioma (DIPG), known to be highly aggressive and difficult to treat brain tumors found at the base of the brain.

[Read More]

FDA grants Merrimack Fast Track for Seribantumab in lung cancer

Monday, July 11, 2016

Merrimack Pharmaceuticals has announced that the FDA has granted seribantumab, also known as MM-121, Fast Track designation for development in patients with heregulin-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed following immunotherapy. Fast Track is a program designed by the FDA to facilitate and expedite the development and review of drugs that treat serious conditions and fill an unmet medical need.

[Read More]